載入中
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
前收盤價
US$1.51
+US$0.02 · +1.34%
盤後
US$1.48
−US$0.03 · -1.99%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日內區間
目前US$1.51
52週區間
目前US$1.51
盤中時間採用ET。市場資料可能有所延遲。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日內區間
目前US$1.51
52週區間
目前US$1.51
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 3759.2萬 USD | 4183.8萬 USD | 4371.7萬 USD | 3791.6萬 USD | 3298.4萬 USD |
| 銷售、一般及管理費用 | 1381.6萬 USD | 1103.9萬 USD | 1204.6萬 USD | 1307萬 USD | 901.8萬 USD |
| 營業費用 | 5140.8萬 USD | 5287.7萬 USD | 5576.3萬 USD | 5098.6萬 USD | 4200.2萬 USD |
| 利息收入 | 467.8萬 USD | 732萬 USD | 651.9萬 USD | 94.7萬 USD | 2.6萬 USD |
| 利息支出 | — | — | 96.4萬 USD | — | — |
| 營業利益 | −5140.8萬 USD | −5287.7萬 USD | −5576.3萬 USD | −5098.6萬 USD | −4200.2萬 USD |
| 淨利 | −4637.7萬 USD | −4300.2萬 USD | −4750.5萬 USD | −4797.8萬 USD | −3790.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI819.12萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM365.17萬0.00%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF302.91萬0.00%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO148.21萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB103.49萬0.01%108.2億 USD0.44%US$204.26-1.08%
Vanguard Health Care ETFVHT75.72萬0.00%220億 USD0.09%US$320.67+0.52%
Schwab U.S. Small-Cap ETFSCHA74.04萬0.00%218.24億 USD0.03%US$32.66-0.40%
iShares Micro-Cap ETFIWC43.07萬0.03%13.17億 USD0.60%US$181.66-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
